Semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, has emerged as the commercial powerhouse, with the oral version launching in January 2026 following December 2025 FDA approval [3]
Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: a double-blind and placebo-controlled clinical trial in healthy women
The more honest comparison is opportunity cost
Common issues include nausea, vomiting, diarrhoea, and constipation, affecting up to 40% of users initially
Your body makes glutathione from three amino acids, cysteine, glycine, and glutamine, which are found in foods like whey protein, bone broth, dark poultry meat, and collagen